Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma

American Society of Clinical Oncology (ASCO) - Tập 20 Số 13 - Trang 2965-2970 - 2002
Lance C. Pagliaro1, Randall E. Millikan2, Shi‐Ming Tu2, Dallas Williams2, Danai Daliani2, Christos Papandreou2, Christopher J. Logothetis2
1Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA. [email protected]
2From the Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Tóm tắt

PURPOSE: We investigated the feasibility, safety, and antitumor activity of weekly gemcitabine given in combination with low doses of cisplatin and ifosfamide in previously treated patients with advanced transitional-cell carcinoma (TCC) of the urothelium. PATIENTS AND METHODS: Patients with measurable, metastatic or unresectable TCC who had received one or two prior chemotherapy regimens were eligible. On a 28-day course, doses of cisplatin 30 mg/m2, gemcitabine 800 mg/m2, and ifosfamide 1 g/m2 were given on day 1 and then repeated on day 8 and day 15 unless there was dose-limiting hematologic toxicity. RESULTS: Fifty-one patients were registered; 10 patients participated in a pilot study, after which 41 patients were registered onto the phase II protocol. Forty-eight patients (94.1%) had dose-limiting hematologic toxicity on day 8 or day 15. Nonhematologic toxicity of grade 3 or greater consisted mainly of nausea and vomiting (seven patients, 13.7%) and infection (seven patients, 13.7%). Responses could be assessed in 49 of 51 eligible patients; two complete responses (4.1%) and 18 partial responses (36.7%) were observed for an overall response rate of 40.8% (exact 95% confidence interval, 27% to 56%). CONCLUSION: This regimen of cisplatin, gemcitabine, and ifosfamide is not feasible for weekly administration because of hematologic toxicity. Nevertheless, there was promising activity with only two doses per 28-day cycle. On the basis of these results, we have initiated a phase II trial of this combination given as a single dose every 14 days in patients with untreated, metastatic urothelial carcinoma.

Từ khóa


Tài liệu tham khảo

10.1016/S0022-5347(17)48996-8

Scher H, Bahnson R, Cohen S, et al: NCCN urothelial cancer practice guidelines. Oncology 12: 225,1998-271,

10.1200/JCO.1992.10.7.1066

10.1200/JCO.2000.18.17.3068

10.1016/S0022-5347(01)66765-X

10.1200/JCO.1997.15.2.589

10.1200/JCO.2001.19.20.4005

10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2

10.1182/blood.V90.1.270

Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23: 3,1996-15, (suppl 10)

10.1002/1097-0142(20010701)92:1<194::AID-CNCR1309>3.0.CO;2-3

10.1200/JCO.2000.18.9.1921

10.1023/A:1008331111654

Marini G, Ferrari VD, Marpicati P, et al: Gemcitabine (GEM) in combination with ifosfamide (IFO) and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC): A phase II study. Proc Am Soc Clin Oncol 18: 516a,1999 (abstr 1989)

Bunn PA: Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Semin Oncol 26: 25,1999-30, (suppl 4)

Simon R: How large should a phase II trial be? Cancer Treat Rep 71: 1079,1987-1085,

10.1080/01621459.1958.10501452

10.1200/JCO.1999.17.10.3173

10.1200/JCO.1994.12.11.2271

10.1200/JCO.1998.16.8.2722

10.1200/JCO.1989.7.1.126

10.1200/JCO.2001.19.12.3018

10.1002/(SICI)1097-0142(19990801)86:3<514::AID-CNCR21>3.0.CO;2-9

10.1023/A:1008344014518

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 20 Số 13

2965-2970

Thông tin tác giả